

MacroGenics Inc

COMPANY AND PIPELINE OVERVIEW REPORT

Coverage of the company and a summary of the drug pipeline portfolio.

Publication Date: 20-Jun-2013

THOMSON REUTERS

3 Times Square
New York, New York 10036
United States

Tel: +1 646 223 4000

thomsonreuters.com

[Return to Table of Contents](#)



ABOUT COMPANY AND PIPELINE OVERVIEW REPORT

Thomson Reuters provides the knowledge, tools, and expertise to help support drug discovery and development activities, IP portfolio optimization, identification of licensing and partnering opportunities, delivery of successful regulatory submissions, and the ability to keep current with the rapidly-changing pharmaceutical and chemical markets, supporting informed, early decisions.

This report was created by Thomson Reuters, using information from *Thomson Reuters Cortellis™ for Competitive Intelligence*; a comprehensive, proven intelligence solution that leverages the most accurate, complete, and widely respected drug pipeline information. From drug discovery and development activities to patent reports, the latest deals, and partnering opportunities, *Cortellis* can provide the confidence to make the most informed business decisions, faster. *Cortellis for Competitive Intelligence* provides accurate and validated information on pharmaceutical and biotechnology companies globally, their drug pipelines, deals, patents, and clinical trials, plus breaking industry news and conference coverage. All contained in one simple, highly intuitive research platform.

Cortellis Company and Pipeline Overview reports are the first in a series of reports that track pharmaceutical and biotechnology companies worldwide. Further report offerings planned to follow include: Company Detailed Pipeline and Company Competitive Landscape reports. All *Cortellis for Competitive Intelligence* content is subject to the most comprehensive editorial review process available, conducted by scientists, pharma professionals, regulatory experts, and generics specialists. Featuring timely drug pipeline information expertly uncovered and integrated from over 400 global meetings each year, you'll always be on top of the latest developments.

Chosen by leading life sciences companies, their executives and investors, *Cortellis for Competitive Intelligence* accelerates your deal-making and gives you timely insights on the development landscape.

Discover undiscovered opportunities in drug development and licensing faster with *Thomson Reuters Cortellis™ for Competitive Intelligence*

DISCLAIMER

The information contained in this report is based on sources believed to be correct but Thomson Reuters does not guarantee the accuracy, timeliness, or completeness of this information. Opinions, if any, are those held by the author of any individual report or article at the time of initial publication and do not necessarily reflect the views of Thomson Reuters.

Information in this report on companies is intended for reference use only, and does not constitute a recommendation to buy or sell any particular security or other investment and does not constitute an offer to buy from or sell to any particular investor. Any company or securities mentioned in this report may not be suitable for any particular investor, depending on that investor's financial position and needs.

[Return to Table of Contents](#)



GLOSSARY

Number of Drugs in Active Development

Number of drugs associated with the company or subsidiary that are currently in active development, i.e. the development status for the drug(s) is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended.

Number of Inactive Drugs

Number of drugs associated with the company or subsidiary that are currently classified as inactive, i.e. where the development status for the drug(s) is one of the following: No Development Reported, Discontinued, or Withdrawn.

Number of Patents as Owner

Number of patents associated with the company where the company is listed as owner; i.e. the relationship type (or way the patent refers to the company) is: Patent Assignee/Owner, Patent owner (not assignee), Licensee for development and marketing, Licensee – marketing only (Distributor), Patent assignee of family member, Inferred assignee.

Number of Patents as Third Party

Number of patents associated with the company where the company is listed as third party; i.e. the relationship type (or way the patent refers to the company) is: Patent assignee (not owner), Ex-Licensee for development and marketing, Ex-Licensee marketing only (Distributor), Customer of technology, Ex-Customer of technology, Patent opponent or infringer, Affiliate organization of inventor, Owner of underlying technology.

Patents summary table

This table represents a summary of the core patent coverage for this company covering Therapeutic EP, US and WO patents since 1990 only.

Number of Deals

A count of deals where the company or one of its subsidiaries is the primary company.

Key Indications

Displays top ten key indications for the company and its subsidiaries based on frequency (indications occurring with high and identical frequency are always included, and this may result in more than ten Key Indications being listed). Includes both indications associated with patents where the company is patent owner and indications associated with drugs in active development. A drug is classified as 'active' if it features on a row (or rows) in the current development status table where the status is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended.

Key Target-based Actions

Displays top ten key target-based actions for the company and its subsidiaries based on frequency (actions occurring with high and identical frequency are always included, and this may result in more than ten Key Target-based Actions being listed). Includes both target-based actions associated with patents where the company patent owner and target-based actions associated with drugs in active development. A drug is classified as 'active' if it features on a row (or rows) in the current development status table where the status is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended. A target-based action is one that is associated with a target.

Key Technologies

Displays top ten key technologies for the company and its subsidiaries based on frequency (technologies occurring with high and identical frequency are always included, and this may result in more than ten Key Technologies being listed). Includes both key technologies associated with patents where the company relationship is patent owner and key technologies associated with drugs in active development. A drug is classified as 'active' if it features on a row (or rows) in the current development status table where the status is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended.

[Return to Table of Contents](#)



TABLE OF CONTENTS

Company Overview..... 5

Company Profile..... 6

Subsidiary Companies..... 7

Product Portfolio Summary..... 7

Product Portfolio Drugs..... 12

[Return to Table of Contents](#)

MacroGenics Inc

COMPANY OVERVIEW

| | |
|---------------------------------------|--|
| Company Name | MacroGenics Inc |
| Parent Company Name | MacroGenics Inc |
| Website | http://www.macrogenics.com/ |
| Country | US |
| Number of Drugs in Active Development | 9 |
| Number of Inactive Drugs | 14 |
| Number of Patents as Owner | 55 |
| Number of Patents as Third Party | 0 |
| Number of Deals | 32 |
| Key Indications | Cancer,Solid tumor,Insulin dependent diabetes,Autoimmune disease,Breast tumor,Inflammatory disease,Variola virus infection,Chikungunya virus infection,Dengue virus infection,Influenza virus infection,Transplant rejection |
| Key Target-based Actions | Immunoglobulin gamma Fc receptor III antagonist,Immunoglobulin gamma Fc receptor II antagonist,ErbB2 tyrosine kinase receptor inhibitor,B-lymphocyte antigen CD20 inhibitor,Insulin-like growth factor 1 antagonist,ADAM-9 modulator,B-lymphocyte antigen CD19 modulator,CD79b agonist,CD80 modulator,Carboxypeptidase inhibitor,Epidermal growth factor antagonist,Immunoglobulin gamma Fc receptor II agonist,Immunoglobulin kappa modulator,Immunoglobulin kappa stimulator,Oncostatin M receptor modulator,Transferrin modulator |
| Key Technologies | Biological therapeutic,Monoclonal antibody humanized,Antibody,Monoclonal antibody,Intravenous formulation,Parenteral formulation unspecified,Chimeric antibody,Humanized antibody,Drug combination,Immunoglobulin-G,Multivalent antibody |

COMPANY PROFILE

SUMMARY

MacroGenics Inc, incorporated in August 2000 and based in Rockville, Maryland, is focused on the development of novel immunotherapeutics. Product candidates include monoclonal antibodies and vaccines for the treatment and prevention of cancer, autoimmune and infectious disease. Programs are derived from both in-house discoveries and in-licensed candidates.

COMPANY LOCATION

MacroGenics is headquartered in Rockville, Maryland. The company has developed platform technology at three sites. These include protein engineering and animal modeling in Rockville, proteomics and target discovery in Seattle, Washington and genetic immunization and vaccine development in Dallas, Texas. In October 2005, MacroGenics opened a cGMP manufacturing facility in Rockville, MD.

ACQUISITIONS AND SPIN-OFFS

In July 2008, MacroGenics acquired Raven Biotechnologies. The company would issue shares of its common stock in the transaction but further financial details were not disclosed.

In June 2002, MacroGenics acquired Eliance Biotechnology Inc, a private vaccine discovery company located in Dallas,TX, which was founded to exploit technology developed at The University of Texas Southwestern Medical Center at Dallas Center for Biomedical Inventions. The company and university also formed an alliance to discover and develop immunotherapeutics to prevent and treat cancer, autoimmune and infectious diseases. In the same month, MacroGenics raised \$12.6 million in financing.

LICENSING AGREEMENTS

In October 2004, MacroGenics acquired exclusive rights to develop compounds against a cancer target identified using

[Return to Table of Contents](#)



OriGene Technologies Inc's Rapid-Scan technology. MacroGenics was to focus on the development of therapeutic monoclonal antibody candidates against this molecule. OriGene would receive option fees, milestones and royalty payments.

In April 2004, Neose Technologies Inc and MacroGenics entered into a monoclonal antibodies research collaboration and license agreement. Neose was to apply its GlycoAdvance and GlycoPEGylation technologies to improve the therapeutic properties of MacroGenics compounds. MacroGenics had the right to take remodeled compounds into development. Following the initial research phase, MacroGenics was to be responsible for funding the further development of these licensed compounds. In exchange, Neose was to be entitled to receive option fee, milestone, and royalty payments as products were developed and commercialized.

In May 2002, MacroGenics licensed a therapeutic target induced by Epstein-Barr virus from EBVax Inc and Tufts University. MacroGenics was to launch a research program to identify treatments to reduce morbidity in patients suffering from the acute and chronic consequences of EBV infection. For a worldwide, exclusive license to the technology, MacroGenics agreed to certain upfront fees, milestone and royalty payments contingent on achieving specific preclinical and clinical objectives in different clinical indications.

In September 2001, MacroGenics reported the completion of several key license agreements relating to its core intellectual property.

EARLY R&D

IN OCTOBER 2010, BOEHRINGER INGELHEIM AND MACROGENICS ENTERED A GLOBAL ALLIANCE TO DISCOVER, DEVELOP AND COMMERCIALIZE ANTIBODY THERAPEUTICS, BASED ON MACROGENICS' DUAL-AFFINITY RE-TARGETING (DART) PLATFORM, WHICH WOULD BE DIRECTED AGAINST UP TO TEN COMBINATIONS OF MOLECULAR TARGETS. THERAPEUTIC AREAS FOR THE DRUG CANDIDATES COULD INCLUDE IMMUNOLOGY, ONCOLOGY, RESPIRATORY, CARDIOMETABOLIC AND INFECTIOUS DISEASES. THE COMPANIES WOULD SHARE DISCOVERY AND CERTAIN PRECLINICAL ACTIVITY RESPONSIBILITY. AFTERWHICH, BOEHRINGER INGELHEIM WOULD BE SOLELY RESPONSIBLE FOR FURTHER PRECLINICAL, CLINICAL, REGULATORY, COMMERCIAL AND MANUFACTURING ACTIVITIES OF ANY RESULTING PRODUCTS. MACROGENICS WAS EXPECTED TO RECEIVE \$60 MILLION, COMPRISED OF AN UPFRONT CASH PAYMENT, ANNUAL MAINTENANCE FEES, R&D FUNDING, AND NEAR-TERM RESEARCH-BASED MILESTONES, DURING THE FIRST THREE YEARS OF THE ALLIANCE. BOEHRINGER INGELHEIM ALSO EXPECTED TO MAKE A FUTURE EQUITY INVESTMENT IN MACROGENICS. FURTHERMORE, MACROGENICS COULD RECEIVE DEVELOPMENT, REGULATORY AND COMMERCIAL MILESTONE PAYMENTS OF UP TO \$210 MILLION FOR EACH OF THE TEN DART PROGRAMS, PLUS TIERED ROYALTIES. MACROGENICS WOULD HAVE AN OPTION TO COPROMOTE CERTAIN DART PRODUCTS IN THE US.

FINANCIAL

In September 2008, MacroGenics raised \$25 million from a series D-2 financing round.

In May 2006, MacroGenics raised \$45 million from a series C financing round. The proceeds were to be used to fund development of the company's anti-CD3 antibody; in phase II trials for type 1 diabetes and to advance drug programs in autoimmune diseases and cancer.

SUBSIDIARY COMPANIES

Names

Raven Biotechnologies Inc

[Return to Table of Contents](#)




PRODUCT PORTFOLIO SUMMARY

DRUGS

Drugs by Indication

Active Drugs by Indication Chart



Drugs by Indication Table


| Indication | Active | Inactive | Total |
|--------------------|--------|----------|-------|
| Neoplasm | 3 | 10 | 13 |
| Infectious disease | 4 | 2 | 6 |
| Immune disorder | 2 | 4 | 6 |

[Return to Table of Contents](#)

| | | | |
|---------------------------|---|---|---|
| Gastrointestinal disease | 1 | 3 | 4 |
| Respiratory disease | 1 | 3 | 4 |
| Genitourinary disease | 0 | 3 | 3 |
| Endocrine disease | 2 | 1 | 3 |
| Inflammatory disease | 1 | 1 | 2 |
| Hematological disease | 0 | 2 | 2 |
| Gynecology and obstetrics | 1 | 1 | 2 |
| Neurological disease | 0 | 2 | 2 |
| Dermatological disease | 0 | 1 | 1 |
| Andrology | 0 | 1 | 1 |
| Metabolic disorder | 1 | 0 | 1 |
| Musculoskeletal disease | 0 | 1 | 1 |

Drugs by Highest Status

Active Drugs by Highest Status Chart



Drugs by Highest Status Table

| Development Status | Number of Drugs |
|--------------------|-----------------|
| Phase 3 Clinical | 1 |
| Phase 2 Clinical | 1 |

[Return to Table of Contents](#)

| | |
|-------------------------|----|
| Phase 1 Clinical | 1 |
| Discovery | 6 |
| Discontinued | 3 |
| No Development Reported | 11 |

DEALS

| Deal Type | Principal | | Partner | | Total |
|--|-----------|----------|---------|----------|-------|
| | Active | Inactive | Active | Inactive | |
| Technology - Other Proprietary | 3 | 0 | 1 | 0 | 4 |
| Drug - Funding | 6 | 0 | 0 | 0 | 6 |
| Drug - Screening/Evaluation | 2 | 0 | 0 | 0 | 2 |
| Drug - Early Research/Development | 1 | 0 | 3 | 0 | 4 |
| Drug - Development/Commercialization License | 8 | 0 | 4 | 0 | 13 |
| Drug - Manufacturing/Supply | 0 | 0 | 1 | 0 | 1 |
| Drug - Development Services | 0 | 0 | 1 | 0 | 1 |
| Technology - Delivery/Formulation | 0 | 0 | 1 | 0 | 1 |

CLINICAL TRIALS

Trials by Condition Studied

| Condition Studied | Ongoing | All |
|---------------------------|---------|-----|
| Gastrointestinal disease | 1 | 8 |
| Endocrine disease | 2 | 8 |
| Metabolic disorder | 0 | 6 |
| Neoplasm | 3 | 5 |
| Immune disorder | 0 | 3 |
| Inflammatory disease | 0 | 3 |
| Infectious disease | 0 | 3 |
| Neurological disease | 0 | 3 |
| Musculoskeletal disease | 0 | 2 |
| Gynecology and obstetrics | 2 | 2 |
| Dermatological disease | 0 | 1 |

[Return to Table of Contents](#)



| | | |
|-----------------------|---|---|
| Genitourinary disease | 1 | 1 |
| Respiratory disease | 1 | 1 |

Trials by Phase

| Phase | Ongoing | All |
|---------------------|---------|-----|
| Phase 3 | 0 | 2 |
| Phase 2 | 1 | 5 |
| Phase 1 | 2 | 9 |
| Phase not specified | 0 | 1 |

Phase Definitions

Phase 3 Clinical

Includes Phase 3, Phase 3b, Phase 3a, Phase 2/3 (where enrolment count is 300 or over)

Phase 2 Clinical

Includes Phase 2, Phase 2a, Phase 2b, Phase 1/2 (where enrolment count is 100 or over), Phase 2/3 (where enrolment count is under 300 or not specified)

Phase 1 Clinical

Includes Phase 1, Phase 1a, Phase 1, Phase 1/2 (where enrolment count is under 100 or not specified), Phase 0

PATENTS *

| Indication | As Owner | As Third Party | Total |
|--------------------------|----------|----------------|-------|
| Cardiovascular disease | 2 | 0 | 2 |
| Endocrine disease | 20 | 0 | 20 |
| Gastrointestinal disease | 19 | 0 | 19 |
| Genitourinary disease | 13 | 0 | 13 |
| Hematological disease | 9 | 0 | 9 |
| Andrology | 8 | 0 | 8 |
| Immune disorder | 31 | 0 | 31 |
| Musculoskeletal disease | 13 | 0 | 13 |
| Neoplasm | 43 | 0 | 43 |
| Ocular disease | 3 | 0 | 3 |
| Metabolic disorder | 10 | 0 | 10 |
| Mouth disease | 1 | 0 | 1 |
| Neurological disease | 10 | 0 | 10 |

[Return to Table of Contents](#)

| | | | |
|--------------------------------|----|---|----|
| Respiratory disease | 11 | 0 | 11 |
| Infectious disease | 18 | 0 | 18 |
| Injury | 1 | 0 | 1 |
| Toxicity and intoxication | 1 | 0 | 1 |
| Inflammatory disease | 23 | 0 | 23 |
| Otorhinolaryngological disease | 1 | 0 | 1 |
| Gynecology and obstetrics | 14 | 0 | 14 |
| Dermatological disease | 13 | 0 | 13 |
| Surgical procedure | 1 | 0 | 1 |

* This table represents a summary of the core patent coverage for this company covering Therapeutic EP, US and WO patents since 1990 only.

[Return to Table of Contents](#)

PRODUCT PORTFOLIO DRUGS

PLEASE NOTE: Highest status refers to highest development of that drug for one of the active companies

teplizumab

| | |
|-----------------------------|--|
| Drug Name | teplizumab |
| Key Synonyms | teplizumab |
| Originator Company | Tolera Therapeutics Inc |
| Active Companies | MacroGenics Inc |
| Inactive Companies | Tolera Therapeutics Inc, Eli Lilly & Co |
| Highest Status | Phase 3 Clinical |
| Active Indications | Transplant rejection, Insulin dependent diabetes |
| Target-based Actions | |
| Other Actions | Anti-inflammatory, Immunosuppressant, Hypoglycemic agent, CD3 antagonist |
| Technologies | Monoclonal antibody, Subcutaneous formulation, Intravenous formulation, Infusion, Biological therapeutic |
| Last Change Date | 05-Oct-2012 |

margetuximab

| | |
|-----------------------------|--|
| Drug Name | margetuximab |
| Key Synonyms | margetuximab |
| Originator Company | MacroGenics Inc |
| Active Companies | MacroGenics Inc, Green Cross Corp |
| Inactive Companies | |
| Highest Status | Phase 2 Clinical |
| Active Indications | Solid tumor, Breast tumor |
| Target-based Actions | ErbB2 tyrosine kinase receptor inhibitor |
| Other Actions | Anticancer monoclonal antibody, Anticancer protein kinase inhibitor |
| Technologies | Monoclonal antibody, Intravenous formulation, Infusion, Biological therapeutic |
| Last Change Date | 11-Jun-2013 |

[Return to Table of Contents](#)



MGA-271

| | |
|-----------------------------|--|
| Drug Name | MGA-271 |
| Key Synonyms | |
| Originator Company | MacroGenics Inc |
| Active Companies | Servier, MacroGenics Inc |
| Inactive Companies | |
| Highest Status | Phase 1 Clinical |
| Active Indications | Solid tumor |
| Target-based Actions | CD80 modulator, Immunoglobulin kappa modulator, Immunoglobulin kappa stimulator |
| Other Actions | Immunostimulant, Anticancer monoclonal antibody |
| Technologies | Monoclonal antibody humanized, Immunoglobulin-G, Intravenous formulation, Biological therapeutic |
| Last Change Date | 15-Feb-2013 |

monoclonal antibody cocktail (DART, smallpox), MacroGenics

| | |
|-----------------------------|---|
| Drug Name | monoclonal antibody cocktail (DART, smallpox), MacroGenics |
| Key Synonyms | |
| Originator Company | MacroGenics Inc |
| Active Companies | MacroGenics Inc |
| Inactive Companies | |
| Highest Status | Discovery |
| Active Indications | Variola virus infection |
| Target-based Actions | |
| Other Actions | Antiviral, Unspecified drug target |
| Technologies | Monoclonal antibody humanized, Drug combination, Biological therapeutic, Parenteral formulation unspecified |
| Last Change Date | 14-Feb-2013 |

[Return to Table of Contents](#)


H5N1 influenza mAb therapy, MacroGenics

| | |
|-----------------------------|---|
| Drug Name | H5N1 influenza mAb therapy, MacroGenics |
| Key Synonyms | |
| Originator Company | MacroGenics Inc |
| Active Companies | MacroGenics Inc |
| Inactive Companies | |
| Highest Status | Discovery |
| Active Indications | Influenza virus infection |
| Target-based Actions | |
| Other Actions | Antiviral, Unspecified drug target |
| Technologies | Monoclonal antibody humanized, Biological therapeutic, Parenteral formulation unspecified |
| Last Change Date | 15-Feb-2013 |

CD32BxCD79B DART antibody (autoimmune disease), MacroGenics

| | |
|-----------------------------|---|
| Drug Name | CD32BxCD79B DART antibody (autoimmune disease), MacroGenics |
| Key Synonyms | |
| Originator Company | MacroGenics Inc |
| Active Companies | MacroGenics Inc |
| Inactive Companies | |
| Highest Status | Discovery |
| Active Indications | Inflammatory disease, Autoimmune disease |
| Target-based Actions | Immunoglobulin gamma Fc receptor II agonist, CD79b agonist |
| Other Actions | Anti-inflammatory, Anticancer |
| Technologies | Antibody, Biological therapeutic |
| Last Change Date | 19-Nov-2012 |

[Return to Table of Contents](#)



monoclonal antibody (DART, dengue virus infection), MacroGenics

| | |
|-----------------------------|---|
| Drug Name | monoclonal antibody (DART, dengue virus infection), MacroGenics |
| Key Synonyms | |
| Originator Company | MacroGenics Inc |
| Active Companies | MacroGenics Inc |
| Inactive Companies | |
| Highest Status | Discovery |
| Active Indications | Dengue virus infection |
| Target-based Actions | |
| Other Actions | Unspecified drug target, Antiviral |
| Technologies | Immunoglobulin, Monoclonal antibody, Biological therapeutic, Parenteral formulation unspecified |
| Last Change Date | 15-Feb-2013 |

bispecific antibodies (DART, cancer), MacroGenics/ Pfizer

| | |
|-----------------------------|--|
| Drug Name | bispecific antibodies (DART, cancer), MacroGenics/ Pfizer |
| Key Synonyms | |
| Originator Company | MacroGenics Inc |
| Active Companies | Pfizer Inc, MacroGenics Inc |
| Inactive Companies | |
| Highest Status | Discovery |
| Active Indications | Cancer |
| Target-based Actions | Epidermal growth factor antagonist, B-lymphocyte antigen CD19 modulator, Insulin-like growth factor 1 antagonist |
| Other Actions | Anticancer antibody, CD3 agonist, Anticancer protein kinase inhibitor |
| Technologies | Multivalent antibody, Biological therapeutic |
| Last Change Date | 19-Nov-2012 |

[Return to Table of Contents](#)



humanized mAbs (Chikungunya virus infection), MacroGenics/Washington University

| | |
|-----------------------------|---|
| Drug Name | humanized mAbs (Chikungunya virus infection), MacroGenics/Washington University |
| Key Synonyms | |
| Originator Company | MacroGenics Inc |
| Active Companies | Washington University in St Louis, MacroGenics Inc |
| Inactive Companies | |
| Highest Status | Discovery |
| Active Indications | Chikungunya virus infection |
| Target-based Actions | |
| Other Actions | Unspecified drug target, Antiviral |
| Technologies | Monoclonal antibody humanized, Biological therapeutic, Parenteral formulation unspecified |
| Last Change Date | 14-Feb-2013 |

[Return to Table of Contents](#)



This report was created by Thomson Reuters, using information from *Thomson Reuters Cortellis™ for Competitive Intelligence*; a comprehensive, proven intelligence solution that leverages the most accurate, complete, and widely respected drug pipeline information.

For more information about *Cortellis for Competitive Intelligence*, visit:

http://cortellis.thomsonreuters.com/cortellis_for_you/?cid=thomsonone.

For subscription information, e-mail scientific.lifesciences@thomsonreuters.com.

© 2012 Thomson Reuters. All rights reserved.
Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks and trademarks of Thomson Reuters and its affiliated companies.

[Return to Table of Contents](#)

